Could this pill beat long COVID fatigue?

NCT ID NCT07298005

Recruiting now Symptom relief Sponsor: Michele van Vugt Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether the drug sonlicromanol can reduce fatigue in 80 people with long COVID who experience post-exertional malaise (worsening symptoms after activity). Participants take the drug or a placebo twice daily for 13 weeks, and researchers measure changes in fatigue, muscle strength, and thinking ability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sonlicromanol
What this could lead to: If it works, this could point toward a treatment for severe fatigue in people with long COVID.
What could go wrong: This is a small, early-phase trial with only 80 participants. The drug may not reduce fatigue better than a placebo, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST COVID CONDITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST COVID CONDITION

Contacts and locations

Show contact details

Locations

Amsterdam University Medical Center, Location Academic Medical Center (AMC)
RECRUITING

Amsterdam, North Holland, 1105 AZ, Netherlands

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.